{'fraction_non_alphanumeric': 0.03868471953578337, 'fraction_numerical': 0.01160541586073501, 'mean_word_length': 6.295774647887324, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Soluble syndecan‐1 (SDC1) serum level as an independent pre‐operative predictor of cancer‐specific survival in prostate cancer

PSA‐screening detects many cases of clinically non‐aggressive prostate cancer (PC) leading to significant overtreatment. Therefore, pre‐operatively available prognostic biomarkers are needed to help therapy decisions. Syndecan‐1 (SDC1) is a promising prognostic tissue marker in several cancers including PC but serum levels of shedded SDC1‐ectodomain (sSDC1) have not been assessed in PC.